BR112017020945A2 - sais maleato de um inibidor de quinase b-raf, formas cris-talinas, métodos de preparação e usos dos mesmos - Google Patents

sais maleato de um inibidor de quinase b-raf, formas cris-talinas, métodos de preparação e usos dos mesmos

Info

Publication number
BR112017020945A2
BR112017020945A2 BR112017020945A BR112017020945A BR112017020945A2 BR 112017020945 A2 BR112017020945 A2 BR 112017020945A2 BR 112017020945 A BR112017020945 A BR 112017020945A BR 112017020945 A BR112017020945 A BR 112017020945A BR 112017020945 A2 BR112017020945 A2 BR 112017020945A2
Authority
BR
Brazil
Prior art keywords
preparation
methods
crystalline forms
kinase inhibitor
raf kinase
Prior art date
Application number
BR112017020945A
Other languages
English (en)
Other versions
BR112017020945B1 (pt
Inventor
Guoliang Zhang
Changyou Zhou
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of BR112017020945A2 publication Critical patent/BR112017020945A2/pt
Publication of BR112017020945B1 publication Critical patent/BR112017020945B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42Separation; Purification; Stabilisation; Use of additives
    • C07C51/43Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/145Maleic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo patente de invenção: sais maleato de um inibidor de quinase b-raf, formas cristalinas, métodos de preparação e usos dos mesmos " a presente invenção refere-se a 5 - ((1r, 1as, 6br) -1- (6- (triflu-orometil) -1h-benzo [d] imidazol-2-il) -1a, 6b-di-hidro-1h-ciclopropa [ b] ben-zofuran-5-il) oxi) -3,4-di-hidro-1,8-naftiridin-2 (1h) -ona (composto 1), em particular ao sal sesqui-maleato e as suas formas cristalinas, a métodos de preparação, composições farmacêuticas e usos terapêuticos para o trata-mento de doenças ou distúrbios mediados por braf ou outras quinases.
BR112017020945-4A 2015-04-15 2016-04-14 Sais cristalinos de sesqui-maleato de um inibidor de quinase b-raf, método e processo de preparação e usos dos mesmos BR112017020945B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2015/076639 2015-04-15
CN2015076639 2015-04-15
PCT/CN2016/079251 WO2016165626A1 (en) 2015-04-15 2016-04-14 Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore

Publications (2)

Publication Number Publication Date
BR112017020945A2 true BR112017020945A2 (pt) 2018-07-10
BR112017020945B1 BR112017020945B1 (pt) 2023-07-04

Family

ID=

Also Published As

Publication number Publication date
US10351559B2 (en) 2019-07-16
CN107531682A (zh) 2018-01-02
KR102643609B1 (ko) 2024-03-05
NZ735715A (en) 2022-09-30
SG11201707984TA (en) 2017-11-29
IL287740A (en) 2021-12-01
CN113307805A (zh) 2021-08-27
KR20240049684A (ko) 2024-04-16
MX2017013219A (es) 2018-02-15
EA035680B1 (ru) 2020-07-24
CA2981746A1 (en) 2016-10-20
IL255555B (en) 2021-12-01
TWI792406B (zh) 2023-02-11
ZA201706392B (en) 2019-05-29
TW201702241A (zh) 2017-01-16
JP7320741B2 (ja) 2023-08-04
AU2016248376B2 (en) 2020-10-08
JP2021073246A (ja) 2021-05-13
TW202330526A (zh) 2023-08-01
EP3283486A1 (en) 2018-02-21
US20180127412A1 (en) 2018-05-10
AU2016248376A1 (en) 2017-10-12
JP7383652B2 (ja) 2023-11-20
CA2981746C (en) 2023-08-01
TWI736531B (zh) 2021-08-21
EP3283486A4 (en) 2018-08-22
JP2018511634A (ja) 2018-04-26
TWI832668B (zh) 2024-02-11
WO2016165626A1 (en) 2016-10-20
TW202138370A (zh) 2021-10-16
KR20170139073A (ko) 2017-12-18
CN107531682B (zh) 2021-05-04
EP3283486B1 (en) 2022-07-27
IL255555A (en) 2018-01-31
EA201792254A1 (ru) 2018-02-28
JP2024012540A (ja) 2024-01-30
EP4119559A1 (en) 2023-01-18

Similar Documents

Publication Publication Date Title
MX2017013219A (es) Sales de maleato de un inhibidor de b-raf quinasa, formas cristalinas, metodos de preparacion y por consiguiente sus usos.
PH12019502269A1 (en) Quinazoline derivatives for the treatment of viral infections and further diseases
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
PH12017500166A1 (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
PH12016502168B1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
EA201591727A1 (ru) Соединения биариламида в качестве ингибиторов киназы
NZ733174A (en) Quinazoline derivatives used to treat hiv
EA201370166A1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
WO2016100347A3 (en) Small molecule inhibitors of egfr and pi3k
BR112015029090A8 (pt) 3,4-dihidroisoquinolin- 2(1h)-ila, seus usos, composição farmacêuticas e sua forma cocristalina
EA201892415A1 (ru) Полиморфная форма n-{6-(2-гидроксипропан-2-ил)-2-[2-(метилсульфонил)этил]-2н-индазол-5-ил}-6-(трифторметил)пиридин-2-карбоксамида
WO2014155300A3 (en) Substitued pyrimidine amine derivatives as tak-1 inhibitors
PH12016502353A1 (en) Pharmaceutical composition
WO2016109217A3 (en) Btk inhibitors
TN2017000158A1 (en) Carbazole derivatives
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos
NZ706591A (en) Oxazolidin-2-one-pyrimidine derivatives
GB201302704D0 (en) Therapeutic compounds
EA201792445A1 (ru) Новые амидогетероарилароилгидразидэтины
EA201791881A1 (ru) Производные 2-аминопиридина в качестве антагонистов рецептора аденозина aи лигандов рецепторов мелатонина mt
BR112019000509A2 (pt) composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica
BR112015023078A2 (pt) inibidores de pirrolopirimindina cdk9 quinase
PH12016502432A1 (en) 1h-1,8-naphthyridin-2-ones as anti proliferative compounds
AR122753A2 (es) Inhibidores selectivos de proteínas cinasas delta pi3k, composiciones farmacéuticas, usos, y métodos de tratamiento y/o prevención de las enfermedades o trastornos mediados por cinasas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/04/2016, OBSERVADAS AS CONDICOES LEGAIS